Considering its short half-life, endogenous FGF21 is not suitable for clinical application; therefore, long-acting FGF21 analogs have been used in preclinical trials for the treatment of obesity and associated metabolic disorders [11, 14, 15]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.